These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 38604141)
1. Lipophilic Ready-to-use Vehicles and Compounded Topical Medications. Lacassia C; Spennacchio A; Lopalco A; Lopedota AA; la Forgia FM; Fontana S; Franco M; Denora N Int J Pharm Compd; 2024; 28(2):146-150. PubMed ID: 38604141 [TBL] [Abstract][Full Text] [Related]
2. Hydrophilic Ready-to-use Vehicles and Compounded Topical Medications. Spennacchio A; Lacassia C; Lopalco A; Lopedota AA; la Forgia FM; Fontana S; Franco M; Denora N Int J Pharm Compd; 2024; 28(2):138-145. PubMed ID: 38604140 [TBL] [Abstract][Full Text] [Related]
3. Prevalence, determinants, and characteristics of extemporaneous compounding in Jordanian pharmacies. AlKhatib HS; Jalouqa S; Maraqa N; Ratka A; Elayeh E; Al Muhaissen S BMC Health Serv Res; 2019 Nov; 19(1):816. PubMed ID: 31703672 [TBL] [Abstract][Full Text] [Related]
4. Analysis of Extemporaneous Prescriptions Prescribed by Dermatovenerologists in Latvia and Comparison with Standardized Compounded Preparation Monographs of Germany and USA. Kiseļova O; Mauriņa B; Šidlovska V Medicina (Kaunas); 2020 Jan; 56(1):. PubMed ID: 31936697 [TBL] [Abstract][Full Text] [Related]
5. Pharmaceutical compounding of orphan active ingredients in Belgium: how community and hospital pharmacists can address the needs of patients with rare diseases. Vanhoorne V; Peeters E; Van Tongelen I; Boussery K; Wynendaele E; De Spiegeleer B; Remon JP; Vervaet C Orphanet J Rare Dis; 2019 Aug; 14(1):186. PubMed ID: 31370862 [TBL] [Abstract][Full Text] [Related]
6. Extemporaneous compounding activities and the associated informational needs of pharmacists. Crawford SY; Dombrowski SR Am J Hosp Pharm; 1991 Jun; 48(6):1205-10. PubMed ID: 1858798 [TBL] [Abstract][Full Text] [Related]
7. Critical appraisal of commercially available suspending vehicles for extemporaneous compounding of cardiovascular medicines: physical and chemical stability mini review. Thrimawithana TR; D'Amore S; Dib Y; Fadavi Firooz N; Fakhouri W; Saeed A; Allahham A Pharm Dev Technol; 2019 Jun; 24(5):529-538. PubMed ID: 30238838 [TBL] [Abstract][Full Text] [Related]
8. A Drug Content, Stability Analysis, and Qualitative Assessment of Pharmacists' Opinions of Two Exemplar Extemporaneous Formulations. Kirkby M; Moffatt K; Rogers AM; McCague PJ; McElnay JC; Quinn C; McCullough LA; Barry J; Donnelly RF Molecules; 2020 Jul; 25(13):. PubMed ID: 32640709 [TBL] [Abstract][Full Text] [Related]
9. Compounded medication for patients with rare diseases. Dooms M; Carvalho M Orphanet J Rare Dis; 2018 Jan; 13(1):1. PubMed ID: 29301541 [TBL] [Abstract][Full Text] [Related]
10. A review of the clinical indications, general principles and techniques related to compounding. Campbell EH; Elston DM; Straughan CL J Am Acad Dermatol; 2020 Jul; 83(1):179-183. PubMed ID: 31669439 [TBL] [Abstract][Full Text] [Related]
11. Magistral formulations and pruritus therapy - What is established, what is confirmed, what is new? Staubach P; Metz M J Dtsch Dermatol Ges; 2013 Nov; 11(11):1049-55. PubMed ID: 24119119 [TBL] [Abstract][Full Text] [Related]
12. Extemporaneous compounding of oral liquid dosage formulations and alternative drug delivery methods for anticancer drugs. Lam MS Pharmacotherapy; 2011 Feb; 31(2):164-92. PubMed ID: 21275495 [TBL] [Abstract][Full Text] [Related]
13. Natural surfactant-based topical vehicles for two model drugs: Influence of different lipophilic excipients on in vitro/in vivo skin performance. Savić S; Weber C; Savić MM; Müller-Goymann C Int J Pharm; 2009 Nov; 381(2):220-30. PubMed ID: 19616085 [TBL] [Abstract][Full Text] [Related]
14. Guiding Clinical Prescription of Topical Extemporaneous Formulations of Sodium Cromoglycate Based on Pharmaceutical Performance. González-González O; Leal E; Martín-Martínez M; Bautista L; Ballesteros MP; Torrado JJ; Serrano DR Pharmaceutics; 2023 May; 15(6):. PubMed ID: 37376057 [TBL] [Abstract][Full Text] [Related]
15. Extemporaneous drug formulations. Nahata MC; Allen LV Clin Ther; 2008 Nov; 30(11):2112-9. PubMed ID: 19108799 [TBL] [Abstract][Full Text] [Related]
16. Basics of Compounding: Vehicles for Compounded Oral Liquid Medications: A Review. Cutaia K; Chablani L; Zhao F Int J Pharm Compd; 2018; 22(6):480-489. PubMed ID: 30384349 [TBL] [Abstract][Full Text] [Related]
17. Stability of an alternative extemporaneous captopril fast-dispersing tablet formulation versus an extemporaneous oral liquid formulation. Pabari RM; McDermott C; Barlow J; Ramtoola Z Clin Ther; 2012 Nov; 34(11):2221-9. PubMed ID: 23149007 [TBL] [Abstract][Full Text] [Related]
19. Galenics of dermal products--vehicles, properties and drug release. Daniels R; Knie U J Dtsch Dermatol Ges; 2007 May; 5(5):367-83. PubMed ID: 17451381 [TBL] [Abstract][Full Text] [Related]
20. Mixing In a Compounding Pharmacy in the 21st Century. Standridge R Int J Pharm Compd; 2015; 19(6):479-84. PubMed ID: 26891562 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]